ATE482720T1 - Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen - Google Patents

Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen

Info

Publication number
ATE482720T1
ATE482720T1 AT03792365T AT03792365T ATE482720T1 AT E482720 T1 ATE482720 T1 AT E482720T1 AT 03792365 T AT03792365 T AT 03792365T AT 03792365 T AT03792365 T AT 03792365T AT E482720 T1 ATE482720 T1 AT E482720T1
Authority
AT
Austria
Prior art keywords
cell lysates
tumor cell
induced tumor
lysate
producing temperature
Prior art date
Application number
AT03792365T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Ute Schoeber
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Application granted granted Critical
Publication of ATE482720T1 publication Critical patent/ATE482720T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
AT03792365T 2002-08-16 2003-08-18 Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen ATE482720T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018512 2002-08-16
PCT/EP2003/009140 WO2004018659A1 (en) 2002-08-16 2003-08-18 Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds

Publications (1)

Publication Number Publication Date
ATE482720T1 true ATE482720T1 (de) 2010-10-15

Family

ID=31896837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792365T ATE482720T1 (de) 2002-08-16 2003-08-18 Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen

Country Status (9)

Country Link
US (1) US7595192B2 (de)
EP (1) EP1530628B1 (de)
AT (1) ATE482720T1 (de)
AU (1) AU2003260426A1 (de)
DE (1) DE60334382D1 (de)
DK (1) DK1530628T3 (de)
ES (1) ES2353753T3 (de)
SI (1) SI1530628T1 (de)
WO (1) WO2004018659A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
CA2557725C (en) * 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
CN101052709B (zh) * 2004-10-25 2012-06-27 贝勒研究院 装载热激黑素瘤细胞体的树突细胞
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
CL2007002825A1 (es) * 2007-09-28 2008-05-30 Univ De Chile Oncobiomed Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
EP2281844A1 (de) 2009-07-31 2011-02-09 Glycotope GmbH MUC-1-Antikörper
EP2748302B1 (de) 2011-08-22 2018-08-15 Glycotope GmbH Mikroorganismen mit einem tumor-antigen
CN103800896A (zh) * 2012-11-15 2014-05-21 厦门鹭佳生物科技有限公司 一种自体肿瘤疫苗的制备方法及其应用
CN112646778A (zh) * 2012-12-28 2021-04-13 阿姆弗拉公司 免疫原性裂解物制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及药物组合物
EP3794042B1 (de) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Conjugue agent cytotoxique et anticorps anti-muc1-exatecan
WO2021016261A2 (en) * 2019-07-22 2021-01-28 Todd Alamin Cell treatments and therapeutic reinfusion methods
WO2024026505A2 (en) * 2022-07-29 2024-02-01 Amit Patel Disruption of telocyte activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DK1654353T3 (da) * 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf

Also Published As

Publication number Publication date
US20060127419A1 (en) 2006-06-15
EP1530628B1 (de) 2010-09-29
SI1530628T1 (sl) 2011-02-28
EP1530628A1 (de) 2005-05-18
US7595192B2 (en) 2009-09-29
DE60334382D1 (de) 2010-11-11
ES2353753T3 (es) 2011-03-04
WO2004018659A1 (en) 2004-03-04
DK1530628T3 (da) 2011-01-10
AU2003260426A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DE60334382D1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
WO2023102550A3 (en) Compositions and methods for efficient in vivo delivery
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
CY1122672T1 (el) Βελτιωμενα nanobodiestm εναντι του παραγοντα νεκρωσης ογκων αλφα
ATE493441T1 (de) Multispezifische deimmunisierte cd3-bindende moleküle
DOP2022000060A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
MX2020012327A (es) Anticuerpo antagonista de cd73.
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2014028453A3 (en) Natural killer cells and uses thereof
SG146682A1 (en) Modulation of eif4e expression
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
JP2020511131A5 (de)
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
JP2016513478A5 (de)
EA201071252A1 (ru) Способ получения 5-(2-аминопиримидин-4-ил)-2-арил-1н-пиррол-3-карбоксамидов
MX2024003615A (es) Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
BRPI0610968A2 (pt) composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
RU2008130457A (ru) Опухолевая вакцина, содержащая аллогенные или ксеногенные опухолевые клетки
DE60331228D1 (de) Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
WO2005018540A3 (en) Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1530628

Country of ref document: EP